822 A1A NORTH, PONTE VEDRA, FL
Market cap: $14.8M (12/18/2025)
Price: $7.11
Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)
Appoints Dr. Lee Golden to Board of Directors
Cadrenal Therapeutics Files Prospectus Supplement for $3.4M Stock Offering
Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Shareholder votes
Enhances Anticoagulation Pipeline Through Acquisition of eXIthera’s Portfolio of Factor XIa Inhibitors
Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease (ESKD) Transitioning to Dialysis
Q3
Q2
Q1
FY 2024
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Notice of Proposed Sale of Securities
Post-Effective Amendment to Registration Statement
Correspondence
Submission Upload
SEC Staff Correspondence